At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C
In Brief
A Phase 2 clinical trial evaluating telaprevir or matching placebo, peginterferon alfa-2a, and 2 other interventions for Hepatitis C and HIV Infections. Completed, enrolled 62 participants across 16 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).
Study Details
Timeline
Interventions
Tablet, Oral, 750 mg, q8h, 12 weeks
Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
Subcutaneous injection, 180 μg, once weekly, 48 weeks
Tablet, Oral, 800 mg, b.i.d., 48 weeks
Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks